| AASLD

<div>Background: Newborn Screening (NBS) is successful in identifying infants with fatal but treatable disorders enabling early intervention with favorable outcomes. Unfortunately, many congenital disorders in particular Wilson disease do not feature specific metabolic biomarkers nor analytical methods suitable for NBS even where highly effective preemptive treatments are available.

AN AGE-STATIN INTERPLAY IN PREVENTING THE DEVELOPMENT OF CIRRHOSIS IN A 10-YEAR COHORT OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Read more about AN AGE-STATIN INTERPLAY IN PREVENTING THE DEVELOPMENT OF CIRRHOSIS IN A 10-YEAR COHORT OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

<div>Background: Statins reduce the risk of hepatic fibrosis in patients with chronic liver diseases. Since age, sex, and menopausal status modulate NAFLD pathogenesis and fibrosis risk, the effects of statins on hepatic fibrosis may vary by age and sex. We aimed to assess age-/sex-disparities in the association between statin use and the incidence of cirrhosis in patients with NAFLD.

AMONG YOUNG ADULTS SURVIVING A FIRST PRESENTATION OF ACUTE ALCOHOLIC HEPATITIS, FEMALES ARE AT 50% HIGHER RISK OF PROGRESSION TO CIRRHOSIS AND DECOMPENSATION

Read more about AMONG YOUNG ADULTS SURVIVING A FIRST PRESENTATION OF ACUTE ALCOHOLIC HEPATITIS, FEMALES ARE AT 50% HIGHER RISK OF PROGRESSION TO CIRRHOSIS AND DECOMPENSATION

<div>Background: Alcohol related harms to adolescents and young adults (AYAs) are on the rise and a priority group for identification and treatment to prevent progression of alcohol-associated liver disease (ALD). Females are at higher risk of developing ALD compared to males secondary to biologic and social-cultural factors. However, whether this sex difference persists after an episode of acute alcoholic hepatitis (AH) is unknown.

NURSE CARE COORDINATION IN CHRONIC LIVER FAILURE REDUCES READMISSIONS FROM HEPATIC ENCEPHALOPATHY AND IMPROVES QUALITY OF CARE; RESULTS FROM THE MULTICENTRE RANDOMIZED CONTROLLED ALFIE TRIAL

Read more about NURSE CARE COORDINATION IN CHRONIC LIVER FAILURE REDUCES READMISSIONS FROM HEPATIC ENCEPHALOPATHY AND IMPROVES QUALITY OF CARE; RESULTS FROM THE MULTICENTRE RANDOMIZED CONTROLLED ALFIE TRIAL

<div>Background: Emergency admissions related to chronic liver failure (CLF) are common, expensive and associated with frequent readmission. There are no multicenter randomized controlled trials (RCT) investigating models to reduce liver-related emergency admissions (LREA).

SINGLE ANASTOMOSIS DOUDENO-ILEAL BYPASS WITH SLEEVE GASTRECTOMY ALLEVIATES LIVER STIFFNESS AND CONTROLLED ATTENUATION PARAMETER IN OBESE PATIENTS – COMPARISON OF 4 MODALITIES

Read more about SINGLE ANASTOMOSIS DOUDENO-ILEAL BYPASS WITH SLEEVE GASTRECTOMY ALLEVIATES LIVER STIFFNESS AND CONTROLLED ATTENUATION PARAMETER IN OBESE PATIENTS – COMPARISON OF 4 MODALITIES

<div>Background: <div>Obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD) are becoming increasingly prevalent. Bariatric surgery, combining weight loss with metabolic improvements, may represent an effective treatment for these disease entities in obese patients with single anastomosis doudeno-ileal bypass with sleeve gastrectomy (SADI-S) representing a novel bariatric procedure.

UNMASKING THE HIDDEN PATTERNS: MACHINE LEARNING IDENTIFIES AND PREDICTS CLUSTERS WITH DISTINCT PROFILES AND OUTCOMES IN ACUTE-ON-CHRONIC LIVER FAILURE (CLUSTER-ACLF)

Read more about UNMASKING THE HIDDEN PATTERNS: MACHINE LEARNING IDENTIFIES AND PREDICTS CLUSTERS WITH DISTINCT PROFILES AND OUTCOMES IN ACUTE-ON-CHRONIC LIVER FAILURE (CLUSTER-ACLF)

<div>Background: Heterogeneity among patients with acute-on-chronic liver failure (ACLF) confer variable outcomes (mortality-range: 0-100%). While prognostic scores capture the known associations, machine learning (ML) can identify the intricate hidden patterns between patient characteristics without any explicit hypothesis or labelling that remain unexplored in ACLF. We employed ML to explore, describe, and predict unknown clusters in ACLF patients.

LONG-TERM RISK OF LIVER-RELATED AND NON-LIVER-RELATED DEATH AFTER DIRECT-ACTING ANTIVIRAL-MEDIATED SUSTAINED VIROLOGIC RESPONSE IN HEPATITIS C VIRUS PATIENTS

Read more about LONG-TERM RISK OF LIVER-RELATED AND NON-LIVER-RELATED DEATH AFTER DIRECT-ACTING ANTIVIRAL-MEDIATED SUSTAINED VIROLOGIC RESPONSE IN HEPATITIS C VIRUS PATIENTS

<div>Background: Direct-acting antiviral (DAA) treatment enables almost all patients with hepatitis C virus (HCV), including those with decompensated cirrhosis to achieve sustained virologic response (SVR), and improves prognosis in SVR patients. However, factors associated with long-term prognosis after SVR are unclear. The aim of this study is to clarify the risk factors for long-term prognosis according to liver-related and non-liver-related death.

THE CIRRHOSIS MEDICAL HOME: A PILOT RANDOMIZED TRIAL OF A COLLABORATIVE CARE MODEL FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

Read more about THE CIRRHOSIS MEDICAL HOME: A PILOT RANDOMIZED TRIAL OF A COLLABORATIVE CARE MODEL FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

<div>Background: Patients with decompensated cirrhosis have poor quality of life and complex care needs that could be addressed with existing services; but the fragmented healthcare system does not provide the necessary coordination to best care for this population. Collaborative care models (CCM) can bridge this gap by providing coordinated, personalized care using care coordinators. In this pilot randomized trial, we developed and tested a CCM for cirrhosis: The Cirrhosis Medical Home (CMH).

SPATIALLY RESOLVED EXPANSION OF REGULATORY IMMUNE CELLS MAY PREDICT CLINICAL OUTCOMES IN PEDIATRIC ACUTE LIVER FAILURE

Read more about SPATIALLY RESOLVED EXPANSION OF REGULATORY IMMUNE CELLS MAY PREDICT CLINICAL OUTCOMES IN PEDIATRIC ACUTE LIVER FAILURE

<div>Background: Pediatric acute liver failure (PALF) remains a poorly-characterized disease entity that affects children of all ages. Emerging data supports an underlying immune-mediated process driving progression and severity. Up to 25% of patients will require liver transplantation (LT), yet there are no reliable indicators of disease trajectory to guide clinicians.

HEPATIC STELLATE CELL-SPECIFIC GLYCOLYSIS REGULATES SPATIAL GENE ZONATION AND CELLULAR INTERACTIONS TO PROMOTE IN VIVO LIVER FIBROSIS.

Read more about HEPATIC STELLATE CELL-SPECIFIC GLYCOLYSIS REGULATES SPATIAL GENE ZONATION AND CELLULAR INTERACTIONS TO PROMOTE IN VIVO LIVER FIBROSIS.

<div>Background: Hepatic stellate cells (HSCs) are the main drivers of liver fibrosis. During The Liver Meeting 2022, we demonstrated that glycolysis deficiency selectively in HSCs attenuated liver fibrosis in vivo. The aim of the present study is to understand how HSC-specific glycolysis promotes liver fibrosis by altering signaling pathways and HSC interactions with the surrounding cell types in a spatial manner.

Subscribe to